On 2/7/25, Rigel Pharmaceuticals Inc (NASDAQ: RIGL) stock suffered a major decline of -10.0%, closing at $21.94. However, trading volume in this decline was below average at 80% of normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -2.9% during the last week.
Current PriceTarget Research Rating
Rigel Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment